Patents by Inventor Mark E. Fitzgerald

Mark E. Fitzgerald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20250121069
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: July 17, 2024
    Publication date: April 17, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • P53 MODULATORS
    Publication number: 20250120961
    Abstract: Disclosed are p53 modulators represented by the following structural formula I: The variables in structural formula I are described herein. Also disclosed are method of treating cancer in a subject with the disclosed p53 modulators, particularly cancers with dysfunctional p53.
    Type: Application
    Filed: June 27, 2024
    Publication date: April 17, 2025
    Inventors: David Belanger, Yongxin Han, Jeffrey Hale, Daniel F. Ortwine, Aysegul Ozen, Matthew Hurley, Kamran Haider, Mark E. Fitzgerald, Michael Hale
  • THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF
    Publication number: 20250115580
    Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.
    Type: Application
    Filed: December 13, 2024
    Publication date: April 10, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Christopher G. Nasveschuk, Katrina L. Jackson, Yanke Liang, Martin Duplessis, Mark E. Fitzgerald, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Juergen Wichmann
  • Degrader Compounds and Uses Thereof
    Publication number: 20240424111
    Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: June 21, 2022
    Publication date: December 26, 2024
    Inventors: Gesine Kerstin VEITS, Mark E. FITZGERALD, Alexander W. HIRD, Ramzi F. SWEIS, Michael E. KORT
  • Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
    Publication number: 20240383886
    Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: November 21, 2024
    Inventors: Gesine Kerstin Veits, Mark E. Fitzgerald, Alexander W. Hird, James A. Henderson, Harit U. Vora, Ramzi F. Sweis, Michael E. Kort, Christopher G. Nasveschuk, Martin Duplessis
  • Heterocyclic degronimers for target protein degradation
    Patent number: 12076405
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: September 3, 2024
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF
    Publication number: 20240199581
    Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.
    Type: Application
    Filed: December 8, 2023
    Publication date: June 20, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveshuk, Katrina L. Jackson, Yanke Liang, Robert T. Yu, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Morgan Welzel O'Shea, Gesine Kerstin Veits, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Franceso Tommaso Pettazzoni, Juergen Wichmann
  • COMPOUNDS FOR TARGETED DEGRADATION OF RET
    Publication number: 20230233692
    Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 27, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Christopher G. Naveschuk, Kiel Lazarski, Victoria Garza, Moses Moustakim, Jae Young Ahn, Gesine Kerstin Veits, Morgan Welzel O'Shea, Ryan E. Michael, Jeremy L. Yap, Yanke Liang, Andrew Charles Good, Mark E. Fitzgerald, Robert T. Yu
  • BRAF DEGRADERS
    Publication number: 20230145336
    Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: December 19, 2022
    Publication date: May 11, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20230014124
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: February 1, 2021
    Publication date: January 19, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • TARGETED PROTEIN DEGRADATION
    Publication number: 20220372016
    Abstract: This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.
    Type: Application
    Filed: June 18, 2021
    Publication date: November 24, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Katrina L. Jackson, Minsheng He, Yanke Liang, Mark E. Fitzgerald, Victoria Garza
  • Heterocyclic degronimers for target protein degradation
    Patent number: 10905768
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: February 2, 2021
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • Heterocyclic degronimers for target protein degradation
    Patent number: 10646575
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 12, 2020
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20190076541
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: November 9, 2018
    Publication date: March 14, 2019
    Applicant: C4 Theraprutics, Inc.
    Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES
    Publication number: 20130085157
    Abstract: This disclosure relates to compounds, compositions and methods for the treatment of various disorders. In particular, the disclosure relates to thiazolotriazole and thiazoloimidazole compounds which agonize the activity of the protein TGR5.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 4, 2013
    Inventors: Emilie D. Smith, Mark E. Fitzgerald, Rong Jiang, Robert N. Atkinson, James M. Veal, Kenneth H. Huang